Higs et al. demonstrated that NSCLC patients with detectable IFN-γ mRNA expression in the tumor responded better to durvalumab compared to patients with no detectable levels of IFN-γ [28]. This evidence concerns the gene IFNG and non-small cell lung carcinoma.